SI1957539T1
(sl)
|
2005-12-08 |
2013-05-31 |
Medarex, Inc. |
Humana monoklonska protitelesa proti protein tirozin kinazi 7 (PTK7) in njihova uporaba
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
BR112013013311A2
(pt)
|
2010-11-30 |
2017-09-19 |
Chugai Pharmaceutical Co Ltd |
agente terapêutico de indução de citotoxicidade
|
US8440797B2
(en)
|
2010-12-06 |
2013-05-14 |
Dainippon Sumitomo Pharma Co., Ltd. |
Human monoclonal antibody
|
CN103249833B
(zh)
*
|
2010-12-06 |
2016-06-29 |
大日本住友制药株式会社 |
人单克隆抗体
|
MX354922B
(es)
*
|
2011-06-30 |
2018-03-26 |
Genzyme Corp |
Inhibidores de la activación de las células t.
|
ES2834093T3
(es)
|
2011-07-21 |
2021-06-16 |
Sumitomo Dainippon Pharma Oncology Inc |
Inhibidores de proteína quinasa heterocíclicos
|
UY34887A
(es)
*
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
AU2014230741B2
(en)
*
|
2013-03-15 |
2017-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-LAG-3 binding proteins
|
ES2935257T3
(es)
|
2013-03-15 |
2023-03-03 |
Univ Chicago |
Métodos y composiciones relacionadas con la actividad de las células T
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
EP2992017B1
(en)
|
2013-05-02 |
2020-11-18 |
AnaptysBio, Inc. |
Antibodies directed against programmed death-1 (pd-1)
|
AU2014296887A1
(en)
|
2013-08-02 |
2016-01-28 |
Aduro Biotech Holdings, Europe B.V. |
Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
|
US11273204B2
(en)
|
2013-08-08 |
2022-03-15 |
Cytune Pharma |
IL-15 and IL-15RAPLHA sushi domain based immunocytokines
|
KR102457731B1
(ko)
|
2013-08-08 |
2022-10-21 |
싸이튠 파마 |
병용 약학 조성물
|
RS64268B1
(sr)
*
|
2013-09-20 |
2023-07-31 |
Bristol Myers Squibb Co |
Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
|
EP3049445A4
(en)
|
2013-09-24 |
2017-10-25 |
Medicenna Therapeutics, Inc. |
Interleukin-2 fusion proteins and uses thereof
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
KR20240017102A
(ko)
*
|
2013-12-17 |
2024-02-06 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
BR112016013741A2
(pt)
*
|
2013-12-17 |
2017-10-03 |
Genentech Inc |
Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
|
WO2015090230A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
GB201322626D0
(en)
|
2013-12-19 |
2014-02-05 |
Immutep S A |
Combined preparations for the treatment of cancer
|
CN106029663B
(zh)
|
2013-12-24 |
2018-06-01 |
百时美施贵宝公司 |
作为抗癌剂的新颖三环化合物
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
EA201691361A1
(ru)
|
2014-01-28 |
2016-12-30 |
Бристол-Маерс Сквибб Компани |
Антитела к lag-3 для лечения гематологических злокачественных опухолей
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
US10144778B2
(en)
|
2014-03-12 |
2018-12-04 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
ME03558B
(me)
*
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
AU2015236369B2
(en)
|
2014-03-24 |
2017-02-16 |
Novartis Ag |
Monobactam organic compounds for the treatment of bacterial infections
|
TWI726842B
(zh)
|
2014-04-07 |
2021-05-11 |
日商中外製藥股份有限公司 |
免疫活化抗原結合分子
|
IL293603B2
(en)
|
2014-04-07 |
2024-03-01 |
Novartis Ag |
Cancer treatment using chimeric antigen receptor (CAR) against CD19
|
CA2946398A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
MX2016014434A
(es)
|
2014-05-13 |
2017-02-23 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
|
BR122018009619B1
(pt)
|
2014-05-16 |
2024-01-02 |
Ablynx N.V |
Domínios variáveis de imunoglobulina aperfeiçoados
|
RU2746738C2
(ru)
|
2014-05-16 |
2021-04-20 |
Аблинкс Нв |
Улучшенные вариабельные домены иммуноглобулина
|
NZ726513A
(en)
|
2014-05-28 |
2023-07-28 |
Memorial Sloan Kettering Cancer Center |
Anti-gitr antibodies and methods of use thereof
|
SG11201610074YA
(en)
|
2014-06-06 |
2016-12-29 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
CA2951259A1
(en)
|
2014-06-06 |
2015-12-10 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
TWI693232B
(zh)
*
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
EP3177593A1
(en)
|
2014-08-06 |
2017-06-14 |
Novartis AG |
Quinolone derivatives as antibacterials
|
US20170216403A1
(en)
|
2014-08-12 |
2017-08-03 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
DK3180018T3
(da)
|
2014-08-12 |
2019-10-28 |
Massachusetts Inst Technology |
Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
JP7084138B2
(ja)
|
2014-08-19 |
2022-06-14 |
ノバルティス アーゲー |
癌処置に使用するための抗cd123キメラ抗原受容体(car)
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
AU2015327868A1
(en)
|
2014-10-03 |
2017-04-20 |
Novartis Ag |
Combination therapies
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
CA2963935A1
(en)
|
2014-10-08 |
2016-04-14 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
KR20170072244A
(ko)
|
2014-10-10 |
2017-06-26 |
이데라 파마슈티칼즈, 인코포레이티드 |
관문 억제제를 가지는 tlr9 효능제를 이용한 암 치료
|
CU20170052A7
(es)
|
2014-10-14 |
2017-11-07 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo que se unen a pd-l1
|
MX2017005462A
(es)
|
2014-11-05 |
2017-07-28 |
Flexus Biosciences Inc |
Agentes inmunorreguladores.
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
AR102537A1
(es)
|
2014-11-05 |
2017-03-08 |
Flexus Biosciences Inc |
Agentes inmunomoduladores
|
EP3789399A1
(en)
|
2014-11-21 |
2021-03-10 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
KR102569813B1
(ko)
|
2014-11-21 |
2023-08-24 |
브리스톨-마이어스 스큅 컴퍼니 |
Cd73에 대항한 항체 및 그의 용도
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
WO2016094639A1
(en)
|
2014-12-10 |
2016-06-16 |
Wisconsin Alumni Research Foundation |
Mini-intronic plasmid dna vaccines in combination with lag3 blockade
|
CN107001295B
(zh)
|
2014-12-16 |
2021-02-02 |
诺华股份有限公司 |
作为LpxC抑制剂的异噁唑异羟肟酸化合物
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
AR103232A1
(es)
|
2014-12-22 |
2017-04-26 |
Bristol Myers Squibb Co |
ANTAGONISTAS DE TGFbR
|
MA40662B1
(fr)
|
2014-12-23 |
2020-12-31 |
Bristol Myers Squibb Co |
Anticorps contre tigit
|
GB201500374D0
(en)
*
|
2015-01-09 |
2015-02-25 |
Immutep S A |
Combined preparations for the treatment of cancer
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
MA41463A
(fr)
*
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
ES2789331T3
(es)
|
2015-03-02 |
2020-10-26 |
Rigel Pharmaceuticals Inc |
Inhibidores de TGF-beta
|
KR20170129802A
(ko)
|
2015-03-10 |
2017-11-27 |
아두로 바이오테크, 인코포레이티드 |
"인터페론 유전자의 자극인자"-의존적 신호전달을 활성화하는 조성물 및 방법
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
AU2016243937A1
(en)
|
2015-04-03 |
2017-11-23 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
|
WO2016164580A1
(en)
|
2015-04-07 |
2016-10-13 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
WO2016162505A1
(en)
|
2015-04-08 |
2016-10-13 |
F-Star Biotechnology Limited |
Her2 binding agent therapies
|
RU2021121771A
(ru)
|
2015-04-08 |
2022-01-12 |
Новартис Аг |
Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19
|
BR112017020952A2
(pt)
|
2015-04-13 |
2018-07-10 |
Five Prime Therapeutics Inc |
método de tratamento de câncer, composição e uso da composição
|
HUE050894T2
(hu)
|
2015-04-17 |
2021-01-28 |
Bristol Myers Squibb Co |
Kompozíciók, amelyek tartalmazzák ipilimumab és nivolumab kombinációját
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
PL3291679T3
(pl)
|
2015-05-06 |
2022-04-25 |
Snipr Technologies Limited |
Zmiana populacji drobnoustrojowych i modyfikowanie mikrobioty
|
ES2815683T3
(es)
|
2015-05-11 |
2021-03-30 |
Bristol Myers Squibb Co |
Compuestos tricíclicos como agentes antineoplásicos
|
US10174024B2
(en)
|
2015-05-12 |
2019-01-08 |
Bristol-Myers Squibb Company |
5H-pyrido[3,2-B]indole compounds as anticancer agents
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
DK3303394T3
(da)
|
2015-05-29 |
2020-07-06 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
MY188049A
(en)
|
2015-05-29 |
2021-11-12 |
Bristol Myers Squibb Co |
Antibodies against ox40 and uses thereof
|
EA039293B1
(ru)
*
|
2015-06-05 |
2021-12-30 |
Мерк Шарп И Доум Корп. |
Антитела против lag3 и антигенсвязывающие фрагменты
|
TWI773646B
(zh)
*
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
US20160376373A1
(en)
|
2015-06-24 |
2016-12-29 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
EA201890162A1
(ru)
|
2015-06-29 |
2018-07-31 |
Бристол-Маерс Сквибб Компани |
Антитела к cd40 с повышенной агонистической активностью
|
HUE053966T2
(hu)
|
2015-07-14 |
2021-08-30 |
Bristol Myers Squibb Co |
Eljárás rák kezelésére immunellenõrzõpont inhibitorral, antitest, amely köt programozott halál-1 receptorhoz (PD-1) vagy programozott halál ligandum 1-hez (PD-L1)
|
JP2018521983A
(ja)
|
2015-07-16 |
2018-08-09 |
バイオカイン セラピューティックス リミテッド |
がんを治療するための組成物および方法
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
US9902772B2
(en)
*
|
2015-07-22 |
2018-02-27 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind LAG3
|
EP3328861A1
(en)
|
2015-07-28 |
2018-06-06 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
SI3317301T1
(sl)
|
2015-07-29 |
2021-10-29 |
Novartis Ag |
Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
PT3328419T
(pt)
|
2015-07-30 |
2021-11-26 |
Macrogenics Inc |
Moléculas de ligação pd-1 e métodos de utilização
|
EP3331919A1
(en)
|
2015-08-07 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
JP2018525415A
(ja)
|
2015-08-25 |
2018-09-06 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Tgfベータ受容体アンタゴニスト
|
MA48579A
(fr)
|
2015-09-01 |
2020-03-18 |
Agenus Inc |
Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
|
KR20180042412A
(ko)
|
2015-09-02 |
2018-04-25 |
이뮤텝 에스.에이.에스. |
항-lag-3 항체
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
WO2017055404A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for pd1 and tim3
|
TWI756187B
(zh)
*
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗lag3抗體及其用途
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
EP3371208A1
(en)
|
2015-11-02 |
2018-09-12 |
Five Prime Therapeutics, Inc. |
Cd80 extracellular domain polypeptides and their use in cancer treatment
|
BR112018008891A8
(pt)
|
2015-11-03 |
2019-02-26 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
|
WO2017079746A2
(en)
|
2015-11-07 |
2017-05-11 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
JP6945456B2
(ja)
*
|
2015-11-13 |
2021-10-06 |
マクロジェニクス,インコーポレーテッド |
Lag‐3結合分子及びその使用方法
|
KR102317574B1
(ko)
*
|
2015-11-18 |
2021-10-26 |
머크 샤프 앤드 돔 코포레이션 |
Pd1 및/또는 lag3 결합제
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
WO2017087901A2
(en)
*
|
2015-11-19 |
2017-05-26 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
EA201891121A1
(ru)
|
2015-11-19 |
2018-12-28 |
Бристол-Майерс Сквибб Компани |
Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
|
SI3376857T1
(sl)
*
|
2015-11-20 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Nehumane živali, ki imajo humaniziran gen 3 za aktivacijo limfocitov
|
BR112018010410A8
(pt)
|
2015-11-23 |
2019-02-26 |
Five Prime Therapeutics Inc |
método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
|
CA3007233A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Antibodies and methods of use thereof
|
SG11201804839WA
(en)
|
2015-12-14 |
2018-07-30 |
Macrogenics Inc |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
US10450318B2
(en)
|
2015-12-15 |
2019-10-22 |
Bristol-Myers Squibb Company |
CXCR4 receptor antagonists
|
KR20180086502A
(ko)
*
|
2015-12-16 |
2018-07-31 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항원-결합 단편
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Pd−1に対する抗体分子およびその使用
|
US10392442B2
(en)
|
2015-12-17 |
2019-08-27 |
Bristol-Myers Squibb Company |
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
|
JP2019506844A
(ja)
|
2015-12-18 |
2019-03-14 |
ノバルティス アーゲー |
CD32bを標的とする抗体およびその使用方法
|
WO2017106630A1
(en)
|
2015-12-18 |
2017-06-22 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
EP3393504A1
(en)
|
2015-12-22 |
2018-10-31 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
CN108473569B
(zh)
|
2016-01-11 |
2022-11-22 |
苏黎世大学 |
针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
|
EA038098B1
(ru)
|
2016-02-19 |
2021-07-06 |
Новартис Аг |
Тетрациклические пиридоновые соединения в качестве противовирусных средств
|
SG10201913033UA
(en)
|
2016-03-04 |
2020-03-30 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
SG10201601719RA
(en)
*
|
2016-03-04 |
2017-10-30 |
Agency Science Tech & Res |
Anti-LAG-3 Antibodies
|
BR112018067679A2
(pt)
|
2016-03-04 |
2019-01-15 |
Novartis Ag |
células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso
|
MX2018011204A
(es)
|
2016-03-15 |
2019-03-07 |
Mersana Therapeutics Inc |
Conjugados de anticuerpo-farmaco dirigidos a napi2b y sus metodos de uso.
|
AU2017234192B2
(en)
|
2016-03-16 |
2024-04-04 |
Amal Therapeutics Sa |
Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
|
ES2962269T3
(es)
|
2016-03-24 |
2024-03-18 |
Novartis Ag |
Análogos de nucleósidos alquinil como inhibidores del rinovirus humano
|
JP7038353B2
(ja)
|
2016-04-13 |
2022-03-18 |
ヴィヴィア バイオテック,エス.エル |
エクスビボのbite活性化t細胞
|
JP7038064B2
(ja)
|
2016-04-18 |
2022-03-17 |
セルデックス セラピューティクス インコーポレイテッド |
ヒトcd40に結合するアゴニスト抗体およびその使用
|
KR20190004743A
(ko)
|
2016-05-04 |
2019-01-14 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
WO2017192813A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
EP3452029A4
(en)
|
2016-05-04 |
2019-10-30 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
US10696648B2
(en)
|
2016-05-04 |
2020-06-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
JP2019516682A
(ja)
|
2016-05-04 |
2019-06-20 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法
|
DK3458478T3
(da)
*
|
2016-05-18 |
2021-03-22 |
Boehringer Ingelheim Int |
Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
|
MX2018013868A
(es)
|
2016-05-20 |
2019-02-21 |
Biohaven Pharm Holding Co Ltd |
Uso de agentes de modulacion de glutamato con inmunoterapias para tratar cancer.
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
CN109789177A
(zh)
|
2016-05-27 |
2019-05-21 |
德那翠丝有限公司 |
腺病毒和免疫调节剂组合治疗
|
CN115671292A
(zh)
|
2016-06-10 |
2023-02-03 |
Io治疗公司 |
用于癌症免疫疗法的受体选择性类视黄醇和rexinoid化合物和免疫调节剂
|
AU2017283480A1
(en)
|
2016-06-13 |
2019-01-24 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
CA3026356A1
(en)
|
2016-06-14 |
2017-12-21 |
Novartis Ag |
Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗pd-l1およびil-2サイトカイン
|
CN109311993B
(zh)
|
2016-06-20 |
2022-12-20 |
F-星治疗有限公司 |
Lag-3结合元件
|
SG11201811064TA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Delta Ltd |
Binding molecules binding pd-l1 and lag-3
|
TWI757304B
(zh)
*
|
2016-06-23 |
2022-03-11 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Lag-3抗體、其抗原結合片段及其醫藥用途
|
WO2017223422A1
(en)
|
2016-06-24 |
2017-12-28 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
AU2017290828A1
(en)
|
2016-06-30 |
2019-01-24 |
Virogin Biotech Canada Ltd |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
AU2017297506A1
(en)
|
2016-07-14 |
2019-02-21 |
Bristol-Myers Squibb Company |
Antibodies against TIM3 and uses thereof
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
WO2018017708A1
(en)
|
2016-07-20 |
2018-01-25 |
University Of Utah Research Foundation |
Cd229 car t cells and methods of use thereof
|
WO2018017633A1
(en)
|
2016-07-21 |
2018-01-25 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
EA039718B1
(ru)
*
|
2016-07-21 |
2022-03-03 |
Регенерон Фармасьютикалз, Инк. |
Антитела к lag3 и их применения
|
EP3498840A4
(en)
*
|
2016-08-15 |
2020-05-06 |
National University Corporation Hokkaido University |
ANTI-LAG-3 ANTIBODIES
|
DK3347379T5
(da)
|
2016-08-17 |
2020-06-15 |
Compugen Ltd |
Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf
|
CN109843322A
(zh)
|
2016-08-26 |
2019-06-04 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
TW201811788A
(zh)
|
2016-09-09 |
2018-04-01 |
瑞士商諾華公司 |
作為抗病毒劑之多環吡啶酮化合物
|
US10647767B2
(en)
|
2016-09-19 |
2020-05-12 |
I-Mab Biopharma Co., Ltd. |
Anti-GM-CSF antibodies and uses thereof
|
CA3031170A1
(en)
|
2016-09-21 |
2018-03-29 |
Amal Therapeutics Sa |
Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
|
CA3036564A1
(en)
|
2016-09-23 |
2018-03-29 |
Elstar Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
JP2020500151A
(ja)
|
2016-09-27 |
2020-01-09 |
ボード オブ リージェンツ, ザ ユニヴァーシティー オブ テキサス システム |
マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
WO2018067992A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
CN117586403A
(zh)
*
|
2016-10-11 |
2024-02-23 |
艾吉纳斯公司 |
抗lag-3抗体及其使用方法
|
RU2755903C2
(ru)
|
2016-10-12 |
2021-09-22 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Способы и композиции для tusc2-иммунотерапии
|
JP7212821B2
(ja)
|
2016-10-13 |
2023-01-26 |
チア・タイ・ティエンチン・ファーマシューティカル・グループ・カンパニー・リミテッド |
抗lag-3抗体および組成物
|
TW201819380A
(zh)
|
2016-10-18 |
2018-06-01 |
瑞士商諾華公司 |
作為抗病毒劑之稠合四環吡啶酮化合物
|
AU2017354070A1
(en)
|
2016-11-01 |
2019-05-16 |
Anaptysbio, Inc. |
Antibodies directed against programmed death- 1 (PD-1)
|
UY37463A
(es)
|
2016-11-02 |
2018-05-31 |
Glaxosmithkline Ip No 2 Ltd |
Proteínas de unión
|
US10660909B2
(en)
|
2016-11-17 |
2020-05-26 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
BR112019010878A2
(pt)
|
2016-11-29 |
2019-10-01 |
Lindhofer Horst |
combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos
|
WO2018102786A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
EA201991383A1
(ru)
|
2016-12-07 |
2019-12-30 |
Эйдженус Инк. |
Антитела против ctla-4 и способы их применения
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
US20200095301A1
(en)
|
2016-12-14 |
2020-03-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Il-13 superkine: immune cell targeting constructs and methods of use thereof
|
CN108204958A
(zh)
*
|
2016-12-19 |
2018-06-26 |
伊缪泰普有限公司 |
结合测定
|
US10961239B2
(en)
|
2017-01-05 |
2021-03-30 |
Bristol-Myers Squibb Company |
TGF beta receptor antagonists
|
BR112019014187A2
(pt)
|
2017-01-09 |
2020-02-11 |
Tesaro, Inc. |
Métodos de tratamento de câncer com anticorpos anti-pd-1
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
AU2018207303A1
(en)
|
2017-01-10 |
2019-07-25 |
xCella Biosciences, Inc. |
Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
|
KR102611446B1
(ko)
|
2017-01-20 |
2023-12-06 |
아르커스 바이오사이언시즈 인코포레이티드 |
암-관련 장애의 치료를 위한 아졸로피리미딘
|
CN110650974B
(zh)
|
2017-02-10 |
2024-04-19 |
瑞泽恩制药公司 |
用于免疫-pet成像的放射性标记的抗-lag3抗体
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
CA3051839A1
(en)
|
2017-02-17 |
2018-08-23 |
Bristol-Myers Squibb Company |
Antibodies to alpha-synuclein and uses thereof
|
EP3389702A4
(en)
|
2017-02-22 |
2019-08-14 |
I-Mab |
ANTI-LAG-3 ANTIBODIES AND USES THEREOF
|
WO2018152687A1
(en)
*
|
2017-02-22 |
2018-08-30 |
I-Mab |
Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體-藥物結合物之組合療法
|
CA3057687A1
(en)
|
2017-03-31 |
2018-10-04 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
US20210101980A1
(en)
|
2017-03-31 |
2021-04-08 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
MX2019011916A
(es)
|
2017-04-05 |
2020-01-09 |
Hoffmann La Roche |
Anticuerpos anti-lag3.
|
CA3185303A1
(en)
|
2017-04-05 |
2018-10-11 |
Symphogen A/S |
Combination therapies targeting pd-a, tim-3, and lag-3
|
KR102346336B1
(ko)
*
|
2017-04-05 |
2022-01-04 |
에프. 호프만-라 로슈 아게 |
Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
CN110709422B
(zh)
|
2017-04-19 |
2023-12-26 |
马伦戈治疗公司 |
多特异性分子及其用途
|
US20200085891A1
(en)
|
2017-04-21 |
2020-03-19 |
Sillajen, Inc |
Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
|
CN110831600B
(zh)
|
2017-04-21 |
2023-10-17 |
医肯纳肿瘤学公司 |
吲哚ahr抑制剂和其用途
|
JP2020517699A
(ja)
|
2017-04-26 |
2020-06-18 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
ジスルフィド結合の還元を最小限にする抗体製造法
|
BR112019022515A2
(pt)
*
|
2017-04-27 |
2020-06-16 |
Tesaro, Inc. |
Agentes de anticorpo direcionados contra o gene 3 de ativação linfocitária (lag-3) e usos dos mesmos
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
CA3059769A1
(en)
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
US11789010B2
(en)
|
2017-04-28 |
2023-10-17 |
Five Prime Therapeutics, Inc. |
Methods of treatment with CD80 extracellular domain polypeptides
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
AR111658A1
(es)
|
2017-05-05 |
2019-08-07 |
Novartis Ag |
2-quinolinonas tricíclicas como agentes antibacteriales
|
US11339218B2
(en)
|
2017-05-10 |
2022-05-24 |
Zhejiang Shimai Pharmaceutical Co., Ltd. |
Human monoclonal antibodies against LAG3 and uses thereof
|
JP7090347B2
(ja)
|
2017-05-12 |
2022-06-24 |
ハープーン セラピューティクス,インク. |
メソテリン結合タンパク質
|
WO2018209049A1
(en)
|
2017-05-12 |
2018-11-15 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2018213297A1
(en)
|
2017-05-16 |
2018-11-22 |
Bristol-Myers Squibb Company |
Treatment of cancer with anti-gitr agonist antibodies
|
PL3634417T3
(pl)
|
2017-05-17 |
2023-09-25 |
Arcus Biosciences, Inc. |
Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem
|
CA3064321A1
(en)
|
2017-05-25 |
2018-11-29 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
CA3064333A1
(en)
|
2017-05-29 |
2018-12-06 |
Gamamabs Pharma |
Cancer-associated immunosuppression inhibitor
|
BR112019021847A2
(pt)
|
2017-05-30 |
2020-06-02 |
Bristol-Myers Squibb Company |
Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
|
SI3631454T1
(sl)
|
2017-05-30 |
2023-12-29 |
Bristol-Myers Squibb Company |
Zdravljenje lag-3 pozitivnih tumorjev
|
EP3630842A2
(en)
|
2017-05-30 |
2020-04-08 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
WO2018223002A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd 123 cd3
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
AU2018275894A1
(en)
|
2017-06-02 |
2019-12-12 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
US11542312B2
(en)
|
2017-06-19 |
2023-01-03 |
Medicenna Therapeutics, Inc. |
IL-2 superagonists in combination with anti-PD-1 antibodies
|
WO2018237157A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
|
WO2018234879A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
|
CA3066747A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
CA3067602A1
(en)
|
2017-06-29 |
2019-01-03 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
EP3644993B1
(en)
|
2017-06-30 |
2023-08-02 |
Bristol-Myers Squibb Company |
Amorphous and crystalline forms of ido inhibitors
|
TW201920275A
(zh)
|
2017-07-06 |
2019-06-01 |
荷蘭商米樂斯股份有限公司 |
藉由細胞表現之調控生物活性的抗體
|
IL302133A
(en)
|
2017-07-13 |
2023-06-01 |
Io Therapeutics Inc |
A combination of a rexinoid and retinoid substance with immunomodulatory properties and immunomodulatory substances for cancer treatment
|
CN110914303B
(zh)
*
|
2017-07-13 |
2023-06-02 |
南京维立志博生物科技有限公司 |
结合lag-3的抗体及其用途
|
CN111163798A
(zh)
|
2017-07-20 |
2020-05-15 |
诺华股份有限公司 |
用于抗lag-3抗体的给药方案及其用途
|
ES2932354T3
(es)
|
2017-07-28 |
2023-01-18 |
Bristol Myers Squibb Co |
Dinucleótidos cíclicos como agentes anticáncer
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
MX2020001793A
(es)
|
2017-08-17 |
2020-07-22 |
Ikena Oncology Inc |
Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
|
WO2019035985A1
(en)
|
2017-08-18 |
2019-02-21 |
Tragara Pharmaceuticals, Inc. |
POLYMORPHIC FORM OF TG02
|
CA3073733A1
(en)
*
|
2017-08-30 |
2019-03-07 |
Phanes Therapeutics, Inc. |
Anti-lag-3 antibodies and uses thereof
|
US10953032B2
(en)
|
2017-08-31 |
2021-03-23 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
WO2019046496A1
(en)
|
2017-08-31 |
2019-03-07 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
EP3676278B1
(en)
|
2017-08-31 |
2023-04-12 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
AU2018326617B2
(en)
|
2017-08-31 |
2022-12-01 |
Io Therapeutics, Inc. |
Rar selective agonists in combination with immune modulators for cancer immunotherapy
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES OF THE LATEST
|
AU2018338314A1
(en)
|
2017-09-22 |
2020-04-09 |
Kymera Therapeutics, Inc |
Protein degraders and uses thereof
|
JP7384668B2
(ja)
*
|
2017-10-05 |
2023-11-21 |
第一三共株式会社 |
細胞傷害性t細胞枯渇用組成物
|
WO2019074824A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
US11649212B2
(en)
|
2017-10-09 |
2023-05-16 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11660311B2
(en)
|
2017-10-10 |
2023-05-30 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
CR20200195A
(es)
|
2017-10-13 |
2020-08-14 |
Harpoon Therapeutics Inc |
Proteínas de unión a antigenos de maduraciòn de celulas b
|
EP3694884A1
(en)
|
2017-10-15 |
2020-08-19 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
JP7254821B2
(ja)
|
2017-10-16 |
2023-04-10 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗がん剤としての環状ジヌクレオチド
|
WO2019076277A1
(zh)
*
|
2017-10-17 |
2019-04-25 |
江苏恒瑞医药股份有限公司 |
抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
|
US20210189336A1
(en)
|
2017-10-18 |
2021-06-24 |
Vivia Biotech, S.L. |
Bite-activated car-t cells
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
CN111902159A
(zh)
|
2017-11-01 |
2020-11-06 |
朱诺治疗学股份有限公司 |
对b细胞成熟抗原(bcma)具有特异性的嵌合抗原受体
|
US11603410B2
(en)
|
2017-11-01 |
2023-03-14 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
US11623961B2
(en)
|
2017-11-01 |
2023-04-11 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
JP7167146B2
(ja)
|
2017-11-06 |
2022-11-08 |
ブリストル-マイヤーズ スクイブ カンパニー |
Hpk1阻害剤として有用なイソフラノン化合物
|
CA3081602A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
US20210079015A1
(en)
|
2017-11-17 |
2021-03-18 |
Novartis Ag |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
WO2019104289A1
(en)
|
2017-11-27 |
2019-05-31 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
EP3717907A1
(en)
|
2017-11-30 |
2020-10-07 |
Novartis AG |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
JP7348899B2
(ja)
|
2017-12-08 |
2023-09-21 |
マレンゴ・セラピューティクス,インコーポレーテッド |
多重特異性分子及びその使用
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
CA3086098A1
(en)
|
2017-12-19 |
2019-06-27 |
F-Star Beta Limited |
Fc binding fragments comprising a pd-l1 antigen-binding site
|
JP2021507906A
(ja)
|
2017-12-20 |
2021-02-25 |
ノバルティス アーゲー |
抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
|
EP3727463A1
(en)
|
2017-12-21 |
2020-10-28 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
EP3714901A4
(en)
|
2017-12-22 |
2022-03-02 |
Jiangsu Hengrui Medicine Co., Ltd. |
ANTI-LAG-3 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF
|
US10874743B2
(en)
|
2017-12-26 |
2020-12-29 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
CN109970857B
(zh)
*
|
2017-12-27 |
2022-09-30 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
CN109970856B
(zh)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
WO2019133747A1
(en)
|
2017-12-27 |
2019-07-04 |
Bristol-Myers Squibb Company |
Anti-cd40 antibodies and uses thereof
|
WO2019129137A1
(zh)
*
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
WO2019133847A1
(en)
|
2017-12-29 |
2019-07-04 |
Oncorus, Inc. |
Oncolytic viral delivery of therapeutic polypeptides
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND THEIR USES
|
WO2019140229A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
WO2019141092A1
(zh)
*
|
2018-01-18 |
2019-07-25 |
四川科伦博泰生物医药股份有限公司 |
抗lag-3抗体及其用途
|
SG11202006832YA
(en)
|
2018-01-29 |
2020-08-28 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
KR20200116481A
(ko)
|
2018-01-29 |
2020-10-12 |
메르크 파텐트 게엠베하 |
Gcn2 억제제 및 이의 용도
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
US20200354457A1
(en)
|
2018-01-31 |
2020-11-12 |
Hoffmann-La Roche Inc. |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
WO2019149715A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Stabilized immunoglobulin domains
|
WO2019152743A1
(en)
|
2018-01-31 |
2019-08-08 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
WO2019165315A1
(en)
|
2018-02-23 |
2019-08-29 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists alone or in combination
|
EP3758751A4
(en)
|
2018-02-28 |
2021-11-17 |
Wuxi Biologics Ireland Limited. |
MONOCLONAL ANTIBODIES AGAINST HUMAN LAG-3, METHOD OF MANUFACTURING AND USING THEREOF
|
US20200407365A1
(en)
|
2018-02-28 |
2020-12-31 |
Novartis Ag |
Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
|
KR20200130362A
(ko)
|
2018-03-08 |
2020-11-18 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
EP3768698A4
(en)
|
2018-03-19 |
2022-03-30 |
MultiVir Inc. |
METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSIVE GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER
|
US11661452B2
(en)
|
2018-03-20 |
2023-05-30 |
WuXi Biologics Ireland Limited |
Anti-lag-3 antibody polypeptide
|
AU2019239747A1
(en)
|
2018-03-21 |
2020-10-08 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
SG11202008802QA
(en)
*
|
2018-03-22 |
2020-10-29 |
Keires Ag |
Antagonistic pd-1, pd-l1 and lag-3 binding proteins
|
PE20210665A1
(es)
|
2018-03-23 |
2021-03-31 |
Bristol Myers Squibb Co |
Anticuerpos contra mica y/o micb y sus usos
|
BR112020019418A2
(pt)
|
2018-03-25 |
2021-02-17 |
Snipr Biome Aps. |
tratamento e prevenção de infecções microbianas
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
CN111971306A
(zh)
|
2018-03-30 |
2020-11-20 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
WO2019192432A1
(zh)
|
2018-04-02 |
2019-10-10 |
上海博威生物医药有限公司 |
结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
|
CN110343178B
(zh)
*
|
2018-04-03 |
2022-07-22 |
上海开拓者生物医药有限公司 |
抗人lag-3单克隆抗体及其应用
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
CA3096546A1
(en)
|
2018-04-16 |
2019-10-24 |
Arrys Therapeutics, Inc. |
Ep4 inhibitors and use thereof
|
WO2019204592A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
EP3781599A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
US20230339891A1
(en)
|
2018-05-03 |
2023-10-26 |
Bristol-Myers Squibb Company |
Uracil derivatives as mer-axl inhibitors
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
EP3801617A1
(en)
|
2018-06-01 |
2021-04-14 |
Novartis Ag |
Dosing of a bispecific antibody that bind cd123 and cd3
|
CA3098420A1
(en)
|
2018-06-01 |
2019-12-05 |
Novartis Ag |
Binding molecules against bcma and uses thereof
|
CN113166972A
(zh)
*
|
2018-06-11 |
2021-07-23 |
耶鲁大学 |
新型免疫检查点抑制剂
|
EP3806962A1
(en)
|
2018-06-13 |
2021-04-21 |
Novartis AG |
Bcma chimeric antigen receptors and uses thereof
|
CN110606892B
(zh)
*
|
2018-06-14 |
2023-09-26 |
华博生物医药技术(上海)有限公司 |
一种高亲和力高生物活性的lag-3抗体及其应用
|
CN110615840A
(zh)
*
|
2018-06-19 |
2019-12-27 |
信达生物制药(苏州)有限公司 |
全人源的抗lag-3抗体及其应用
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
WO2020006018A1
(en)
|
2018-06-27 |
2020-01-02 |
Bristol-Myers Squibb Company |
Substituted naphthyridinone compounds useful as t cell activators
|
CA3104647A1
(en)
|
2018-06-27 |
2020-01-02 |
Bristol-Myers Squibb Company |
Naphthyridinone compounds useful as t cell activators
|
KR102250234B1
(ko)
*
|
2018-06-29 |
2021-05-10 |
주식회사 와이바이오로직스 |
Lag-3에 특이적으로 결합하는 단클론항체 및 이의 용도
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
AU2019302454A1
(en)
|
2018-07-09 |
2021-02-25 |
Bristol-Myers Squibb Company |
Antibodies binding to ILT4
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
SG11202011872QA
(en)
|
2018-07-10 |
2021-01-28 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
|
WO2020014327A2
(en)
|
2018-07-11 |
2020-01-16 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic ph
|
WO2020018503A2
(en)
|
2018-07-16 |
2020-01-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-il36r antibodies
|
CA3106114A1
(en)
|
2018-07-20 |
2020-01-23 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
WO2020023355A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US20210355113A1
(en)
|
2018-07-23 |
2021-11-18 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
CN112739371A
(zh)
|
2018-07-26 |
2021-04-30 |
百时美施贵宝公司 |
用于治疗癌症的lag-3组合疗法
|
WO2020038397A1
(en)
*
|
2018-08-21 |
2020-02-27 |
I-Mab |
Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
JP2022500499A
(ja)
|
2018-09-07 |
2022-01-04 |
ピク セラピューティクス, インコーポレイテッド |
Eif4e阻害剤およびその使用
|
EP3849979A1
(en)
|
2018-09-12 |
2021-07-21 |
Novartis AG |
Antiviral pyridopyrazinedione compounds
|
CN112105633B
(zh)
|
2018-09-21 |
2024-03-12 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
TWI801664B
(zh)
|
2018-09-21 |
2023-05-11 |
大陸商信達生物製藥(蘇州)有限公司 |
新型白介素2及其用途
|
US10815311B2
(en)
|
2018-09-25 |
2020-10-27 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
AU2019346645A1
(en)
|
2018-09-27 |
2021-04-29 |
Marengo Therapeutics, Inc. |
CSF1R/CCR2 multispecific antibodies
|
EP3856782A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
EP4282416A3
(en)
|
2018-09-29 |
2024-03-06 |
Novartis AG |
Process of manufacture of a compound for inhibiting the activity of shp2
|
US11358999B2
(en)
|
2018-10-03 |
2022-06-14 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
US11130802B2
(en)
|
2018-10-10 |
2021-09-28 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants
|
MX2021004059A
(es)
|
2018-10-12 |
2021-09-23 |
Xencor Inc |
Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas.
|
SG11202102864XA
(en)
|
2018-10-19 |
2021-05-28 |
Bristol Myers Squibb Co |
Combination therapy for melanoma
|
US20230021500A1
(en)
|
2018-10-29 |
2023-01-26 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
EP3873943A2
(en)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
AU2019374103A1
(en)
|
2018-11-01 |
2021-05-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
|
SG11202105084VA
(en)
|
2018-11-16 |
2021-06-29 |
Juno Therapeutics Inc |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
AU2019380307A1
(en)
|
2018-11-16 |
2021-07-01 |
Bristol-Myers Squibb Company |
Anti-NKG2A antibodies and uses thereof
|
JP2022513685A
(ja)
|
2018-11-30 |
2022-02-09 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いた処置のための方法
|
BR112021010484A2
(pt)
|
2018-11-30 |
2021-08-24 |
Kymera Therapeutics, Inc. |
Degradadores de irak e usos dos mesmos
|
MX2021006544A
(es)
|
2018-12-04 |
2021-07-07 |
Sumitomo Pharma Oncology Inc |
Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
|
JP2022514315A
(ja)
|
2018-12-20 |
2022-02-10 |
ノバルティス アーゲー |
3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体を含む投与計画及び薬剤組み合わせ
|
CN113438961A
(zh)
|
2018-12-20 |
2021-09-24 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
EP3897613A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
AU2019406840A1
(en)
|
2018-12-21 |
2021-06-03 |
Novartis Ag |
Use of IL-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
|
WO2020128620A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1beta binding antibodies
|
JP2022514702A
(ja)
|
2018-12-21 |
2022-02-14 |
オーエスイー・イミュノセラピューティクス |
二機能性抗pd-1/il-7分子
|
EP3898974A1
(en)
|
2018-12-21 |
2021-10-27 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
WO2020154032A1
(en)
|
2019-01-23 |
2020-07-30 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
US20220096651A1
(en)
|
2019-01-29 |
2022-03-31 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
CN113412262A
(zh)
|
2019-02-12 |
2021-09-17 |
大日本住友制药肿瘤公司 |
包含杂环蛋白激酶抑制剂的制剂
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
CA3124935A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
KR20210129672A
(ko)
|
2019-02-15 |
2021-10-28 |
노파르티스 아게 |
치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
|
CN111620949A
(zh)
*
|
2019-02-28 |
2020-09-04 |
三生国健药业(上海)股份有限公司 |
结合人lag-3的抗体、其制备方法和用途
|
CA3133155A1
(en)
|
2019-03-19 |
2020-09-24 |
Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron |
Combination therapy for the treatment for cancer
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
WO2020198077A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
CA3134822A1
(en)
|
2019-03-26 |
2020-10-01 |
The Regents Of The Universtiy Of Michigan |
Small molecule degraders of stat3
|
WO2020205467A1
(en)
|
2019-03-29 |
2020-10-08 |
The Regents Of The University Of Michigan |
Stat3 protein degraders
|
CA3135569A1
(en)
|
2019-04-02 |
2020-10-08 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
US11485750B1
(en)
|
2019-04-05 |
2022-11-01 |
Kymera Therapeutics, Inc. |
STAT degraders and uses thereof
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
GB201906118D0
(en)
|
2019-05-01 |
2019-06-12 |
Immutep S A |
Anti-LAG-3 binding molecules
|
WO2020231766A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
JP2022532490A
(ja)
|
2019-05-13 |
2022-07-15 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ
|
US20230242478A1
(en)
|
2019-05-13 |
2023-08-03 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
CN114127315A
(zh)
|
2019-05-30 |
2022-03-01 |
百时美施贵宝公司 |
鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
|
US20220233691A1
(en)
|
2019-05-30 |
2022-07-28 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
EP3976831A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures for suitability to immuno-oncology therapy
|
CN110320367A
(zh)
*
|
2019-05-30 |
2019-10-11 |
广州医科大学附属第一医院(广州呼吸中心) |
基于lag-3的诊断试剂盒及其在帕金森病诊断产品上的应用
|
KR20220034739A
(ko)
|
2019-05-31 |
2022-03-18 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
CN114341189A
(zh)
|
2019-06-12 |
2022-04-12 |
奥美药业有限公司 |
全新il-15前药及其应用
|
US20220265590A1
(en)
|
2019-06-12 |
2022-08-25 |
Vanderbilt University |
Dibenzylamines as amino acid transport inhibitors
|
EP3983084A1
(en)
|
2019-06-12 |
2022-04-20 |
Vanderbilt University |
Amino acid transport inhibitors and the uses thereof
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
CN114302878A
(zh)
|
2019-07-03 |
2022-04-08 |
大日本住友制药肿瘤公司 |
酪氨酸激酶非受体1(tnk1)抑制剂及其用途
|
IT201900011676A1
(it)
|
2019-07-12 |
2021-01-12 |
St Superiore Di Sanita |
Anticorpo ricombinante umano contro il recettore di membrana LAG3, suoi usi medici e diagnostici.
|
KR20220035116A
(ko)
|
2019-07-16 |
2022-03-21 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
Eed 억제제로서의 이미다조피리미딘 및 이의 용도
|
WO2021026179A1
(en)
|
2019-08-06 |
2021-02-11 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
US20220388978A1
(en)
|
2019-08-27 |
2022-12-08 |
Regents Of The University Of Michigan |
Cereblon e3 ligase inhibitors
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
KR20220105631A
(ko)
|
2019-09-13 |
2022-07-27 |
님버스 새턴 인코포레이티드 |
Hpk1 길항제 및 이의 용도
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
EP4031575A1
(en)
|
2019-09-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
JP2022548775A
(ja)
|
2019-09-19 |
2022-11-21 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
スピロ環式アンドロゲン受容体タンパク質分解剤
|
CA3153777A1
(en)
|
2019-09-22 |
2021-03-25 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
AR120045A1
(es)
|
2019-09-26 |
2022-01-26 |
Novartis Ag |
Compuestos antivirales de pirazolopiridinona
|
CA3157024A1
(en)
|
2019-10-03 |
2021-04-08 |
Xencor, Inc. |
Targeted il-12 heterodimeric fc-fusion proteins
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
BR112022007179A2
(pt)
|
2019-10-21 |
2022-08-23 |
Novartis Ag |
Inibidores de tim-3 e usos dos mesmos
|
KR20220103947A
(ko)
|
2019-10-21 |
2022-07-25 |
노파르티스 아게 |
베네토클락스 및 tim-3 억제제를 사용한 조합 요법
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
BR112022007632A2
(pt)
*
|
2019-10-25 |
2022-07-12 |
Daiichi Sankyo Co Ltd |
Composição farmacêutica e preparação de kit para tratamento de câncer, e, métodos para tratamento de câncer e de um paciente com câncer
|
US20220409642A1
(en)
|
2019-11-04 |
2022-12-29 |
Astrazeneca Ab |
Combination therapy for treating cancer
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
CA3160479A1
(en)
|
2019-11-08 |
2021-05-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for melanoma
|
CN114728950A
(zh)
|
2019-11-19 |
2022-07-08 |
百时美施贵宝公司 |
可作为helios蛋白质抑制剂的化合物
|
US11591339B2
(en)
|
2019-11-26 |
2023-02-28 |
Ikena Oncology, Inc. |
Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors
|
CN115151306A
(zh)
|
2019-11-26 |
2022-10-04 |
百时美施贵宝公司 |
(r)-n-(4-氯苯基)-2-((1s,4s)-4-(6-氟喹啉-4-基)环己基)丙酰胺的盐/共晶
|
US11975026B2
(en)
|
2019-11-26 |
2024-05-07 |
Novartis Ag |
CD19 and CD22 chimeric antigen receptors and uses thereof
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
BR112022011651A2
(pt)
|
2019-12-17 |
2022-08-23 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
AU2020406083A1
(en)
|
2019-12-17 |
2022-06-16 |
Ose Immunotherapeutics |
Bifunctional molecules comprising an IL-7 variant
|
CN115052662A
(zh)
|
2019-12-20 |
2022-09-13 |
诺华股份有限公司 |
抗TGFβ抗体和检查点抑制剂用于治疗增殖性疾病的用途
|
WO2021126967A1
(en)
*
|
2019-12-20 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Lag3 antagonist cell based potency assay
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
KR20220119454A
(ko)
|
2019-12-23 |
2022-08-29 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 치환된 퀴나졸리닐 화합물
|
CN115175907A
(zh)
|
2019-12-23 |
2022-10-11 |
百时美施贵宝公司 |
可用作t细胞激活剂的经取代的哌嗪衍生物
|
WO2021133748A1
(en)
|
2019-12-23 |
2021-07-01 |
Bristol-Myers Squibb Company |
Substituted quinolinonyl piperazine compounds useful as t cell activators
|
BR112022012204A2
(pt)
|
2019-12-23 |
2022-09-13 |
Bristol Myers Squibb Co |
Compostos de heteroarila substituída úteis como ativadores de célula t
|
IL294150A
(en)
|
2019-12-23 |
2022-08-01 |
Kymera Therapeutics Inc |
Smarca joints and their uses
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
AU2021206618A1
(en)
|
2020-01-06 |
2022-08-18 |
Hifibio (Hk) Limited |
Anti-TNFR2 antibody and uses thereof
|
US11534441B2
(en)
|
2020-01-15 |
2022-12-27 |
Blueprint Medicines Corporation |
MAP4K1 inhibitors
|
MX2022008763A
(es)
|
2020-01-17 |
2022-07-27 |
Novartis Ag |
Combinacion que comprende un inhibidor de tim-3 y un agente hipometilante para usarse en el tratamiento del sindrome mielodisplasico o leucemia mielomonocitica cronica.
|
JP2023514152A
(ja)
|
2020-02-06 |
2023-04-05 |
ブリストル-マイヤーズ スクイブ カンパニー |
Il-10およびその使用
|
WO2021171264A1
(en)
|
2020-02-28 |
2021-09-02 |
Novartis Ag |
Dosing of a bispecific antibody that binds cd123 and cd3
|
KR20220164706A
(ko)
|
2020-03-03 |
2022-12-13 |
피아이씨 테라퓨틱스 인코포레이티드 |
Eif4e 억제제 및 이의 용도
|
JP2023516459A
(ja)
|
2020-03-09 |
2023-04-19 |
ブリストル-マイヤーズ スクイブ カンパニー |
増強されたアゴニスト活性を有するcd40に対する抗体
|
BR112022018600A2
(pt)
|
2020-03-19 |
2022-11-08 |
Arcus Biosciences Inc |
Compostos, composição farmacêutica, método de tratamento de uma doença e combinação
|
EP4121043A1
(en)
|
2020-03-19 |
2023-01-25 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
US20230159573A1
(en)
|
2020-03-26 |
2023-05-25 |
The Regents Of The University Of Michigan |
Small molecule stat protein degraders
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
AU2021251265A1
(en)
|
2020-04-10 |
2022-11-03 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
CA3176564A1
(en)
|
2020-05-27 |
2021-12-02 |
Agilent Technologies, Inc. |
Anti-human lag-3 antibodies and their use in immunohistochemistry (ihc)
|
WO2021247591A1
(en)
|
2020-06-02 |
2021-12-09 |
Arcus Biosciences, Inc. |
Antibodies to tigit
|
WO2021245071A1
(en)
|
2020-06-03 |
2021-12-09 |
Mv Biotherapeutics Sa |
Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
CN114605544B
(zh)
*
|
2020-06-05 |
2023-08-01 |
北京天广实生物技术股份有限公司 |
Lag3抗体及其用途
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
JP2023531676A
(ja)
|
2020-06-23 |
2023-07-25 |
ノバルティス アーゲー |
3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン
|
KR20230035576A
(ko)
|
2020-07-07 |
2023-03-14 |
비온테크 에스이 |
Hpv 양성 암 치료용 rna
|
US20230233690A1
(en)
|
2020-07-10 |
2023-07-27 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
WO2022011204A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Small molecule androgen receptor protein degraders
|
EP4188374A1
(en)
|
2020-07-30 |
2023-06-07 |
Kymera Therapeutics, Inc. |
Methods of treating mutant lymphomas
|
CN116134027A
(zh)
|
2020-08-03 |
2023-05-16 |
诺华股份有限公司 |
杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
CN116724051A
(zh)
|
2020-08-10 |
2023-09-08 |
上海寻百会生物技术有限公司 |
用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法
|
KR20230050389A
(ko)
|
2020-08-13 |
2023-04-14 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-2를 관심 표적 세포로 재지시하는 방법
|
CA3186504A1
(en)
|
2020-08-17 |
2022-02-24 |
Stephen J. Blakemore |
Bicycle conjugates specific for nectin-4 and uses thereof
|
CN116761818A
(zh)
|
2020-08-26 |
2023-09-15 |
马伦戈治疗公司 |
检测trbc1或trbc2的方法
|
JP2023540255A
(ja)
|
2020-08-28 |
2023-09-22 |
ブリストル-マイヤーズ スクイブ カンパニー |
肝細胞癌のためのlag-3アンタゴニスト療法
|
WO2022047412A1
(en)
|
2020-08-31 |
2022-03-03 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
JP2023542297A
(ja)
|
2020-09-14 |
2023-10-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
異種プライムブーストワクチン
|
CA3187272A1
(en)
|
2020-10-08 |
2022-04-14 |
Thorsten Ross |
Trispecific binders
|
AU2021360782A1
(en)
|
2020-10-14 |
2023-06-08 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
CA3196496A1
(en)
|
2020-10-23 |
2022-04-28 |
Laurence David TOMS |
Lag-3 antagonist therapy for lung cancer
|
KR20230104651A
(ko)
|
2020-11-06 |
2023-07-10 |
노파르티스 아게 |
Cd19 결합 분자 및 이의 용도
|
WO2022112198A1
(en)
|
2020-11-24 |
2022-06-02 |
Worldwide Innovative Network |
Method to select the optimal immune checkpoint therapies
|
WO2022120354A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2022117572A2
(en)
|
2020-12-02 |
2022-06-09 |
Oncurious Nv |
An ltbr agonist in combination therapy against cancer
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
WO2022125497A1
(en)
|
2020-12-08 |
2022-06-16 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
CN114621344B
(zh)
*
|
2020-12-10 |
2022-08-30 |
北京东方百泰生物科技股份有限公司 |
一种抗lag-3单克隆抗体的纯化方法
|
CA3202330A1
(en)
|
2020-12-16 |
2022-06-23 |
Anthony Casarez |
Compounds useful as t cell activators
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
WO2022146948A1
(en)
|
2020-12-28 |
2022-07-07 |
Bristol-Myers Squibb Company |
Subcutaneous administration of pd1/pd-l1 antibodies
|
IL303648A
(en)
|
2020-12-28 |
2023-08-01 |
Bristol Myers Squibb Co |
Antibody preparations and methods of using them
|
WO2022148781A1
(en)
|
2021-01-05 |
2022-07-14 |
Institut Curie |
Combination of mcoln activators and immune checkpoint inhibitors
|
EP4274597A1
(en)
|
2021-01-11 |
2023-11-15 |
BicycleTX Limited |
Methods for treating cancer
|
AU2022216810A1
(en)
|
2021-02-02 |
2023-08-24 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
AU2022215844A1
(en)
|
2021-02-02 |
2023-09-14 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
JP2024505600A
(ja)
|
2021-02-03 |
2024-02-06 |
モーツァルト セラピューティクス, インコーポレイテッド |
結合剤およびそれを使用する方法
|
US20240109899A1
(en)
|
2021-02-04 |
2024-04-04 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
WO2022171745A1
(en)
|
2021-02-12 |
2022-08-18 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
KR20230145446A
(ko)
|
2021-02-15 |
2023-10-17 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak4 분해제 및 이의 용도
|
US20220275090A1
(en)
|
2021-02-22 |
2022-09-01 |
Janssen Biotech, Inc. |
Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
|
WO2022187419A1
(en)
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Small molecule degraders of androgen receptor
|
WO2022187423A1
(en)
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Cereblon ligands
|
JP2024509192A
(ja)
|
2021-03-05 |
2024-02-29 |
ニンバス サターン, インコーポレイテッド |
Hpk1アンタゴニスト及びその使用
|
EP4305041A1
(en)
|
2021-03-08 |
2024-01-17 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
KR20240005700A
(ko)
|
2021-03-29 |
2024-01-12 |
주노 쎄러퓨티크스 인코퍼레이티드 |
체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
KR20230167067A
(ko)
|
2021-04-05 |
2023-12-07 |
브리스톨-마이어스 스큅 컴퍼니 |
암의 치료를 위한 피리디닐 치환된 옥소이소인돌린 화합물
|
PE20231941A1
(es)
|
2021-04-06 |
2023-12-05 |
Bristol Myers Squibb Co |
Compuestos de oxoisoindolina sustituidos con piridinilo
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
AU2022255506A1
(en)
|
2021-04-08 |
2023-11-09 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
IL307419A
(en)
|
2021-04-09 |
2023-12-01 |
Ose Immunotherapeutics |
A new scaffold for bifunctional molecules with improved properties
|
EP4320156A1
(en)
|
2021-04-09 |
2024-02-14 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
PE20240327A1
(es)
|
2021-04-13 |
2024-02-22 |
Nuvalent Inc |
Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr
|
KR20230172548A
(ko)
|
2021-04-16 |
2023-12-22 |
이케나 온콜로지, 인코포레이티드 |
Mek 억제제 및 이의 용도
|
EP4337694A1
(en)
|
2021-05-12 |
2024-03-20 |
Dana-Farber Cancer Institute, Inc. |
Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
CN117337288A
(zh)
|
2021-05-21 |
2024-01-02 |
艾库斯生物科学有限公司 |
Axl抑制剂化合物
|
CN117295741A
(zh)
|
2021-05-21 |
2023-12-26 |
艾库斯生物科学有限公司 |
Axl化合物
|
AU2022281461A1
(en)
|
2021-05-25 |
2024-01-04 |
Edelweiss Immune Inc |
C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
|
TW202307210A
(zh)
|
2021-06-01 |
2023-02-16 |
瑞士商諾華公司 |
Cd19和cd22嵌合抗原受體及其用途
|
KR20240046323A
(ko)
|
2021-07-13 |
2024-04-08 |
비온테크 에스이 |
암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제
|
AU2022312496A1
(en)
|
2021-07-14 |
2024-02-22 |
Blueprint Medicines Corporation |
Heterocyclic compounds as map4k1 inhibitors
|
AR126453A1
(es)
|
2021-07-15 |
2023-10-11 |
Blueprint Medicines Corp |
Inhibidores de map4k1
|
CA3216098A1
(en)
|
2021-07-30 |
2023-02-02 |
Uwe Reusch |
Duplexbodies
|
IL310924A
(en)
|
2021-08-25 |
2024-04-01 |
Pic Therapeutics Inc |
EIF4E inhibitors and their uses
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
TW202328090A
(zh)
|
2021-09-08 |
2023-07-16 |
美商雷度納製藥公司 |
Papd5及/或papd7抑制劑
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
WO2023077090A1
(en)
|
2021-10-29 |
2023-05-04 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
US20230159466A1
(en)
|
2021-10-29 |
2023-05-25 |
Arcus Biosciences, Inc. |
Inhibitors of hif-2alpha and methods of use thereof
|
WO2023079494A1
(en)
|
2021-11-03 |
2023-05-11 |
Janssen Biotech, Inc. |
Corticosteriod reduction in treatment with anti-cd38 antibodies
|
WO2023111203A1
(en)
|
2021-12-16 |
2023-06-22 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
WO2023147371A1
(en)
|
2022-01-26 |
2023-08-03 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
WO2023150186A1
(en)
|
2022-02-01 |
2023-08-10 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
WO2023154905A1
(en)
|
2022-02-14 |
2023-08-17 |
Gilead Sciences, Inc. |
Antiviral pyrazolopyridinone compounds
|
WO2023164638A1
(en)
|
2022-02-25 |
2023-08-31 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023178192A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
WO2023178201A2
(en)
*
|
2022-03-15 |
2023-09-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of identifying anti-lag-3 agents
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023230205A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024003360A1
(en)
|
2022-07-01 |
2024-01-04 |
Institut Curie |
Biomarkers and uses thereof for the treatment of neuroblastoma
|
WO2024015251A1
(en)
|
2022-07-15 |
2024-01-18 |
Arcus Biosciences, Inc. |
Inhibitors of hpk1 and methods of use thereof
|
WO2024020034A1
(en)
|
2022-07-20 |
2024-01-25 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024028386A1
(en)
|
2022-08-02 |
2024-02-08 |
Ose Immunotherapeutics |
Multifunctional molecule directed against cd28
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
US20240041929A1
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
WO2024036100A1
(en)
|
2022-08-08 |
2024-02-15 |
Bristol-Myers Squibb Company |
Substituted tetrazolyl compounds useful as t cell activators
|
WO2024036101A1
(en)
|
2022-08-09 |
2024-02-15 |
Bristol-Myers Squibb Company |
Tertiary amine substituted bicyclic compounds useful as t cell activators
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024040194A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
WO2024059142A1
(en)
|
2022-09-14 |
2024-03-21 |
Arcus Biosciences, Inc. |
Dispersions of etrumadenant
|
WO2024081385A1
(en)
|
2022-10-14 |
2024-04-18 |
Arcus Biosciences, Inc. |
Hpk1 inhibitors and methods of use thereof
|
WO2024086718A1
(en)
|
2022-10-20 |
2024-04-25 |
Arcus Biosciences, Inc. |
Lyophilized formulations of cd73 compounds
|
WO2024089417A1
(en)
|
2022-10-24 |
2024-05-02 |
Memorial Sloan-Kettering Cancer Center |
Tumour stratification for responsiveness to an immune checkpoint inhibitor
|
WO2024089418A1
(en)
|
2022-10-24 |
2024-05-02 |
Cancer Research Technology Limited |
Tumour sensitisation to checkpoint inhibitors with redox status modifier
|